Skip to main content

Zymeworks Inc(ZYME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.08
Day High9.39
Open:9.33
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
GlobeNewswire
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer
GlobeNewswire
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
GlobeNewswire
Zymeworks Announces Additional Leadership Appointments
GlobeNewswire
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
GlobeNewswire
Zymeworks Added to Nasdaq Biotechnology Index
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conference
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks To Host Third Quarter 2023 Results Conference Call
GlobeNewswire
Zymeworks Announces New Director Nominee
PR Newswire
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks To Host Second Quarter 2023 Results Conference Call
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conference
GlobeNewswire
Zymeworks Appoints New Director
GlobeNewswire
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes

Profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.